Literature DB >> 32971182

Andrographolide suppresses NLRP3 inflammasome activation in microglia through induction of parkin-mediated mitophagy in in-vitro and in-vivo models of Parkinson disease.

Sahabuddin Ahmed1, Mohit Kwatra1, Samir Ranjan Panda1, U S N Murty1, V G M Naidu2.   

Abstract

Cellular communication linking microglia activation and dopaminergic neuronal loss play an imperative role in the progression of Parkinson's disease (PD); however, underlying molecular mechanisms are not precise and require further elucidation. NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome activation is extensively studied in context to microglial activation and progressive dopaminergic neuronal loss in PD. Several pathophysiological factors such as oxidative stress, mitochondrial dysfunction impaired mitophagy plays a crucial role in activating NLRP3 inflammasome complex. Hence, regulation of microglial activation through mitophagy could be a valuable strategy in controlling microglia mediated neurodegeneration. In this study we have developed a model of inflammasome activation by combining LPS with a mitochondrial complex-I inhibitor MPP+. The idea of using MPP+ after priming mouse microglia with LPS was to disrupt mitochondria and release reactive oxygen species, which act as Signal 2 in augmenting NLRP3 assembly, thereby releasing potent inflammatory mediators such as active interleukin-1 beta (IL-1β) and IL-18. LPS-MPP+ combination was seen to impaired the mitophagy by inhibiting the initial step of autophagosome formation as evidenced by protein expression and confocal imaging data. Treatment with Andrographolide promoted the parkin-dependent autophagic flux formation in microglia; resulting in the removal of defective mitochondria which in turn inhibit NLRP3 inflammasome activation. Additionally, the neuroprotective role of Andrographolide in inhibiting NLRP3 activation together with salvage ATP level via promoting parkin-dependent mitophagy was seen in the substantial nigra par compacta (SNpc) region of mice brain. Furthermore, Andrographolide rescued the dopaminergic neuron loss and improved the behavioural parameters in animal model. Collectively, our results reveal the role of mitophagy in the regulation of NLRP3 inflammasome by removing defective mitochondria. In addition, andrographolide was seen to abate NLRP3 inflammasome activation in microglia and rescue dopaminergic neuron loss.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Andrographolide; Mitochondrial dysfunction; Mitophagy; NLRP3 inflammasome

Mesh:

Substances:

Year:  2020        PMID: 32971182     DOI: 10.1016/j.bbi.2020.09.017

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  19 in total

1.  Downregulation of MicroRNA-145-5p in Activated Microglial Exosomes Promotes Astrocyte Proliferation by Removal of Smad3 Inhibition.

Authors:  Yong Ye; Jie Hao; Zhou Hong; Tong Wu; Xingyu Ge; Boyu Qian; Xiaoqing Chen; Feng Zhang
Journal:  Neurochem Res       Date:  2021-10-08       Impact factor: 3.996

Review 2.  Emerging targets signaling for inflammation in Parkinson's disease drug discovery.

Authors:  Rhema Chandan Khairnar; Niraj Parihar; Kedar S Prabhavalkar; Lokesh Kumar Bhatt
Journal:  Metab Brain Dis       Date:  2022-05-10       Impact factor: 3.655

Review 3.  Neurodegenerative Disease and the NLRP3 Inflammasome.

Authors:  Jonathan A Holbrook; Heledd H Jarosz-Griffiths; Emily Caseley; Samuel Lara-Reyna; James A Poulter; Caroline H Williams-Gray; Daniel Peckham; Michael F McDermott
Journal:  Front Pharmacol       Date:  2021-03-10       Impact factor: 5.810

Review 4.  Microglia in Alzheimer's Disease: A Target for Therapeutic Intervention.

Authors:  Guimei Zhang; Zicheng Wang; Huiling Hu; Meng Zhao; Li Sun
Journal:  Front Cell Neurosci       Date:  2021-11-24       Impact factor: 5.505

Review 5.  Mitochondrial Quality Control: A Pathophysiological Mechanism and Therapeutic Target for Stroke.

Authors:  Miaoxian Yang; Yu He; Shuixiang Deng; Lei Xiao; Mi Tian; Yuewen Xin; Chaocheng Lu; Feng Zhao; Ye Gong
Journal:  Front Mol Neurosci       Date:  2022-01-28       Impact factor: 5.639

Review 6.  Targeting Mitochondria by Plant Secondary Metabolites: A Promising Strategy in Combating Parkinson's Disease.

Authors:  Sajad Fakhri; Sadaf Abdian; Seyede Nazanin Zarneshan; Esra Küpeli Akkol; Mohammad Hosein Farzaei; Eduardo Sobarzo-Sánchez
Journal:  Int J Mol Sci       Date:  2021-11-22       Impact factor: 5.923

Review 7.  Systems and Circuits Linking Chronic Pain and Circadian Rhythms.

Authors:  Andrew E Warfield; Jonathan F Prather; William D Todd
Journal:  Front Neurosci       Date:  2021-07-02       Impact factor: 5.152

8.  Mitochondrial and Organellar Crosstalk in Parkinson's Disease.

Authors:  Bipul Ray; Abid Bhat; Arehally Marappa Mahalakshmi; Sunanda Tuladhar; Muhammed Bishir; Surapaneni Krishna Mohan; Vishnu Priya Veeraraghavan; Ramesh Chandra; Musthafa Mohamed Essa; Saravana Babu Chidambaram; Meena Kishore Sakharkar
Journal:  ASN Neuro       Date:  2021 Jan-Dec       Impact factor: 4.146

Review 9.  Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease.

Authors:  Yunna Li; Yun Xia; Sijia Yin; Fang Wan; Junjie Hu; Liang Kou; Yadi Sun; Jiawei Wu; Qiulu Zhou; Jinsha Huang; Nian Xiong; Tao Wang
Journal:  Front Immunol       Date:  2021-10-08       Impact factor: 7.561

10.  Andrographolide alleviates bleomycin-induced NLRP3 inflammasome activation and epithelial-mesenchymal transition in lung epithelial cells by suppressing AKT/mTOR signaling pathway.

Authors:  Jingpei Li; Xiaohan Yang; Penghui Yang; Ke Xu; Xiaomin Peng; Weipeng Cai; Simin Zhao; Lei Hu; Zhuoyi Li; Fei Cui; Wei Wang; Guilin Peng; Xin Xu; Jianxing He; Jun Liu
Journal:  Ann Transl Med       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.